Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

The increased severity of the COVID-19 infection due to new SARS-CoV-2 variants has resonated pandemic impact which made health experts to re-evaluate the effectiveness of pandemic management strategies. This becomes critical owing to the infection in large population and shortcomings in the existing global healthcare system worldwide. The designing of high-performance nanosystems (NS) with tunable performances seems to be the most efficient method to tackle infectious SARS-CoV-2 variants including recently emerged omicron mutation. In this direction, experts projects the versatile functionalized NS and their capabilities to mitigate SARS-CoV-2 propagation pathways by sensitization, antipathogenicity, photocatalysis, photothermal effects, immune response, developing efficient diagnostics assays or associated, selective biomarkers detection, and targeted drug delivery systems. To achieve these tasks, this opinion article project the importance of the fabrication of nano-enabled protective gear, masks, gloves, sheets, filtration units, nano-emulsified disinfectants, antiviral/bacterial paints, and therangostics to facilitate quarantine strategies via protection, detection, and treatment needed to manage COVID-19 pandemic in personalized manners. These functional protective high-performance antibacterial and antiviral NS can efficiently tackle the SARS-CoV-2 variants transmission through respiratory fluids and pollutants within water droplets, aerosols, air, and particulates along with their severe infection via neutralizing or eradicating the virus.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632437PMC
http://dx.doi.org/10.1016/j.cobme.2021.100363DOI Listing

Publication Analysis

Top Keywords

sars-cov-2 variants
16
antibacterial antiviral
8
high-performance nanosystems
8
mitigate sars-cov-2
8
sars-cov-2
5
antiviral high-performance
4
nanosystems mitigate
4
variants
4
variants concern
4
concern increased
4

Similar Publications

The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.

View Article and Find Full Text PDF

New SARS-CoV-2 variants continue to emerge and may cause new waves of COVID-19. Antibody evasion is a major driver of variant emergence but variants can also exhibit altered capacity to enter lung cells and to use ACE2 species orthologues for cell entry. Here, we assessed cell line tropism, usage of ACE2 orthologues and antibody evasion of variant MC.

View Article and Find Full Text PDF

A bivalent SARS-CoV-2 subunit vaccine for cats neutralizes both the original ancestral strain and BA.1 Pseudovirus carrying the 453F and 501 T mutation.

Vaccine

September 2025

College of Veterinary Medicine, Huazhong Agricultural University, Wuhan 430070, China; National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural University, Wuhan 430070, China; Hubei Jiangxia Laboratory, Wuhan 430200, China. Electronic address:

The spillover and spillback of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) between humans and animals, especially companion animals, threaten global public health security. However, risk assessment of SARS-CoV-2 variants infecting companion animals and the development of corresponding prevention and control technologies are lacking. The aim of this study is to assess the potential risk of enhancement of the infectivity of SARS-CoV-2 in cats owing to mutations at key sites within the spike (S) protein receptor-binding domain (RBD) region and develop an efficient vaccine to cross-neutralize high-risk SARS-CoV-2 variants.

View Article and Find Full Text PDF

Background: Obesity was a risk factor for severe COVID-19 in children during early outbreaks of ancestral SARS-CoV-2 and the Delta variant. However, the relationship between obesity and COVID-19 severity during the Omicron wave remains unclear.

Methods: This multicenter, observational study included polymerase chain r eaction-confirmed SARS-CoV-2-infected children and adolescents from Australia, Brazil, Italy, Portugal, Switzerland, Thailand, the United Kingdom and the United States hospitalized between January 1, 2020, and March 31, 2022.

View Article and Find Full Text PDF

The COVID-19 pandemic remains a global health crisis, with successive SARS-CoV-2 variants exhibiting enhanced transmissibility and immune evasion. Notably, the Omicron variant harbors extensive mutations in the spike protein's receptor-binding domain (RBD), altering viral fitness. While temperature is a critical environmental factor modulating viral stability and transmission, its molecular-level effects on variant-specific RBD-human angiotensin-converting enzyme 2 (hACE2) interactions remain underexplored.

View Article and Find Full Text PDF